CAMBRIDGE, Mass.--(BUSINESS WIRE)--Padlock Therapeutics, a biotechnology company dedicated to creating new medicines for destructive autoimmune diseases, today announced the formation of its Scientific Advisory Board (SAB). This group of experts will provide valuable insight, advice, and perspective as the company advances its pipeline of investigational compounds directed at protein-arginine deiminases (PADs). The expertise of the SAB encompasses PAD biology and biochemistry, neutrophil biology, and clinical rheumatology.
Help employers find you! Check out all the jobs and post your resume.
